Hormone therapy can lower risk of broken bones in postmenopausal women

Image
ANI Washington D.C. [USA]
Last Updated : Apr 24 2017 | 10:57 AM IST

Good news! A team of US researchers has found that postmenopausal women, who are at the highest genetic risk of bone fracture, can benefit the most from hormone therapy.

The study included nearly 10,000 participants from the Women's Health Initiative (WHI), a national, long-term study of more than 1,50,000 women.

They included more than 1,61,000 generally healthy postmenopausal women, aged 50 to 79.

"We found that women who are genetically at the highest fracture risk can enjoy the greatest protection from fracture when they use hormone therapy," said lead researcher Heather Ochs-Balcom at the University at Buffalo.

"This study provides a better understanding of who can benefit the most in terms of bone health from hormone therapy use," Ochs-Balcom said, adding that the results have implications for personalised medicine.

The researchers investigated gene-hormone therapy interaction on fracture in postmenopausal white women and utilised the largest set of known genes linked to fracture risk from a meta-analysis of genome-wide association studies.

"This is important because, as previous WHI studies have identified, there are risks and benefits with hormone therapy," Ochs-Balcom said.

"This is where precision or personalised medicine comes in -- the attempt to get the right drugs to the right person to ensure the most benefit and least harm," he explained.

As women age, their Bone Mineral Density (BMD) decreases, leaving them at greater risk of breaking bones from falling, which also increases as they age as some women are also more genetically prone to fractures.

"Our study represents a first look at how inherited predisposition to fracture is related to hormone therapy use," said Ochs-Balcom.

"The research team is currently analyzing other gene-environment interactions and recently published another paper on the association of calcium plus vitamin D supplementation and genetic risk of fracture," they concluded.

The findings appeared in the journal of Clinical Endocrinology and Metabolism.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 24 2017 | 10:57 AM IST

Next Story